Product
VIP152
3 clinical trials
12 indications
Indication
CancerIndication
Relapsed Non-Hodgkin LymphomaIndication
Chronic Lymphocytic LeukemiaIndication
Refractory Chronic Lymphocytic LeukemiaIndication
Richter syndromeIndication
MYC AmplificationIndication
MYC OverexpressionIndication
MYC TranslocationIndication
lymphomaIndication
Non-Hodgkin lymphomaIndication
Hematologic MalignanciesIndication
Lymphoid MalignanciesClinical trial
An Open-label, Multicenter Phase I Dose Escalation Study to Characterize Safety, Tolerability, Preliminary Anti-tumor Activity, Pharmacokinetics and Maximum Tolerated Dose of VIP152 (BAY 1251152) as Monotherapy or Combination Therapy in Subjects With Advanced Cancer.Status: Active (not recruiting), Estimated PCD: 2024-12-30
Clinical trial
An Open-label, Multicenter Phase 1/1b Study to Characterize Safety, Tolerability, Preliminary Antitumor Activity, Pharmacokinetics, and Pharmacodynamics of VIP152 Monotherapy or Combination Therapy in Subjects With High-risk Chronic Lymphocytic Leukemia or Richter SyndromeStatus: Terminated, Estimated PCD: 2023-05-26
Clinical trial
Phase 1/2 Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid MalignanciesStatus: Recruiting, Estimated PCD: 2025-03-10